India & Glenmark Pharmaceuticals
5 shared events · Importance 3 · Last updated Jul 27, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
India: India is the largest supplier of generic drugs to the US; the tariffs threaten its $9.7 billion pharma export market and could force strategic shifts.
Glenmark Pharmaceuticals: Glenmark, along with Lupin, supplied 65% of US birth control pill prescriptions in 2024; tariffs could impact its US revenue.
Jul 21, 2026 · 73 articles
Regulatory
India: India's regulatory framework is being tested; the case could clarify the applicability of drug laws to duty-free shops.
Glenmark Pharmaceuticals: Glenmark is mentioned only as former employer of Murali Neelakantan; not directly involved.
Jul 07, 2026 · 17 articles
Business
India: The event highlights growth in India's BPC manufacturing ecosystem.
Glenmark Pharmaceuticals: Partners with Naturis for cosmeceuticals.
Jul 16, 2026 · 6 articles
Business
Glenmark Pharmaceuticals: Glenmark Pharmaceuticals is among the Indian companies introducing generic semaglutide, contributing to the increased competition in the market.
Mar 30, 2026 · 8 articles
Business
Glenmark Pharmaceuticals: Glenmark Pharmaceuticals is mentioned as one of the companies offering semaglutide products in India, contributing to the overall market competition.
Mar 20, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Glenmark Pharmaceuticals interact across events, view sentiment trends, and discover connected entities.
Open Dashboard